Global Expert Exchange: IO therapy for advanced NSCLC with no oncogenic driver mutations
Chaired by Luis Paz-Ares and Caicun Zhou, an expert panel share their experiences in the treatment of advanced NSCLC with no oncogenic driver mutations and discuss how treatment practices may differ across the globe.
Treatment guidelines for first-line IO in advanced NSCLC
IO-monotherapy for advanced NSCLC with a PD-L1 TPS of ≥50%
First line chemo-IO in advanced NSCLC
Chemo-IO versus IO-IO in advanced NSCLC
Second line and later treatments for advanced NSCLC
IO in patients with a poor patient performance status
IO in patients with comorbidities
IO in patients with CNS metastases
Discussion: Global variations in clinical practice
Clinical case sharing (Europe)
Clinical case sharing (China)
Discussion: Individualizing treatment decisions
Panel discussion



